263 related articles for article (PubMed ID: 31969234)
1. Clinicopathological Characteristics of BRAF V600E Mutated Melanomas in the Dalmatian Region of Croatia.
Bezić J; Kuret S; Vrbičić B; Smolić J; Borić I; Škifić I; Ledina D; Božić J
Acta Dermatovenerol Croat; 2019 Dec; 27(4):225-230. PubMed ID: 31969234
[TBL] [Abstract][Full Text] [Related]
2. Molecular evaluation of BRAF V600 mutation and its association with clinicopathological characteristics: First findings from Indian malignant melanoma patients.
Ahmad F; Avabhrath N; Natarajan S; Parikh J; Patole K; Das BR
Cancer Genet; 2019 Feb; 231-232():46-53. PubMed ID: 30803557
[TBL] [Abstract][Full Text] [Related]
3. Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma.
Pozzobon FC; Puig-Butillé JA; González-Alvarez T; Carrera C; Aguilera P; Alos L; Badenas C; Grichnik JM; Malvehy J; Puig S
Br J Dermatol; 2014 Oct; 171(4):754-9. PubMed ID: 24749938
[TBL] [Abstract][Full Text] [Related]
4. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
5. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
6. The role of BRAF mutations in primary melanoma growth rate and survival.
Mar VJ; Liu W; Devitt B; Wong SQ; Dobrovic A; McArthur GA; Wolfe R; Kelly JW
Br J Dermatol; 2015 Jul; 173(1):76-82. PubMed ID: 25752325
[TBL] [Abstract][Full Text] [Related]
7. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
[TBL] [Abstract][Full Text] [Related]
8. Reflectance confocal microscopy features of BRAF V600E mutated thin melanomas detected by immunohistochemistry.
Urvanegia AC; Tavoloni Braga JC; Shitara D; Fregnani JH; Neves JI; Pinto CA; Marghoob AA; Duprat JP; Rezze GG
PLoS One; 2017; 12(6):e0179745. PubMed ID: 28662062
[TBL] [Abstract][Full Text] [Related]
9. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
Hugdahl E; Kalvenes MB; Puntervoll HE; Ladstein RG; Akslen LA
Br J Cancer; 2016 Mar; 114(7):801-8. PubMed ID: 26924424
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.
Devitt B; Liu W; Salemi R; Wolfe R; Kelly J; Tzen CY; Dobrovic A; McArthur G
Pigment Cell Melanoma Res; 2011 Aug; 24(4):666-72. PubMed ID: 21615881
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
Yaman B; Akalin T; Kandiloğlu G
Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic findings and BRAF mutation in cutaneous melanoma in young adults.
Estrozi B; Machado J; Rodriguez R; Bacchi CE
Appl Immunohistochem Mol Morphol; 2014 Jan; 22(1):57-64. PubMed ID: 24471189
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological characteristics associated with BRAF(K601E) and BRAF(L597) mutations in melanoma.
Voskoboynik M; Mar V; Mailer S; Colebatch A; Fennessy A; Logan A; Hewitt C; Cebon J; Kelly J; McArthur G
Pigment Cell Melanoma Res; 2016 Mar; 29(2):222-8. PubMed ID: 26643848
[TBL] [Abstract][Full Text] [Related]
14. Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma.
Liu W; Kelly JW; Trivett M; Murray WK; Dowling JP; Wolfe R; Mason G; Magee J; Angel C; Dobrovic A; McArthur GA
J Invest Dermatol; 2007 Apr; 127(4):900-5. PubMed ID: 17159915
[TBL] [Abstract][Full Text] [Related]
15. Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas.
Sviatoha V; Tani E; Ghaderi M; Kleina R; Skoog L
Anticancer Res; 2010 Sep; 30(9):3267-72. PubMed ID: 20944096
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
[TBL] [Abstract][Full Text] [Related]
17. KIT Suppresses BRAF
Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
[TBL] [Abstract][Full Text] [Related]
18.
Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
[TBL] [Abstract][Full Text] [Related]
19. Russian study of morphological prognostic factors characterization in BRAF-mutant cutaneous melanoma.
Aksenenko MB; Kirichenko AK; Ruksha TG
Pathol Res Pract; 2015 Jul; 211(7):521-7. PubMed ID: 25888143
[TBL] [Abstract][Full Text] [Related]
20. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
